Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials.
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
received:
18
11
2023
accepted:
17
03
2024
medline:
22
3
2024
pubmed:
22
3
2024
entrez:
22
3
2024
Statut:
epublish
Résumé
Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important clinical trials have improved our understanding of sepsis-associated AKI (SA-AKI) and impacted clinical care. Advances in sub-phenotyping of sepsis and AKI and clinical trial design offer unprecedented opportunities to fill gaps in knowledge and generate better evidence for improving the outcome of critically ill patients with SA-AKI. In this manuscript, we review the recent literature of clinical trials in sepsis with focus on studies that explore SA-AKI as a primary or secondary outcome. We discuss lessons learned and potential opportunities to improve the design of clinical trials and generate actionable evidence in future research. We specifically discuss the role of enrichment strategies to target populations that are most likely to derive benefit and the importance of patient-centered clinical trial endpoints and appropriate trial designs with the aim to provide guidance in designing future trials.
Identifiants
pubmed: 38515121
doi: 10.1186/s13054-024-04877-4
pii: 10.1186/s13054-024-04877-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Informations de copyright
© 2024. The Author(s).
Références
Schulman IH, Chan K, Der JS, et al. Readmission and mortality after hospitalization with acute kidney injury. Am J Kidney Dis. 2023;S0272–6386(23):00067–77. https://doi.org/10.1053/j.ajkd.2022.12.008 .
doi: 10.1053/j.ajkd.2022.12.008
Angus DC, Barnato AE, Bell D, et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe investigators. Intensive Care Med. 2015;41:1549–60. https://doi.org/10.1007/s00134-015-3822-1 .
doi: 10.1007/s00134-015-3822-1
pubmed: 25952825
Kellum JA, Chawla LS, Keener C, et al. The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. Am J Respir Crit Care Med. 2016;193:281–7. https://doi.org/10.1164/rccm.201505-0995OC .
doi: 10.1164/rccm.201505-0995OC
pubmed: 26398704
pmcid: 4803059
Legrand M, Rossignol P. Cardiovascular consequences of acute kidney injury. N Engl J Med. 2020;382:2238–47. https://doi.org/10.1056/NEJMra1916393 .
doi: 10.1056/NEJMra1916393
pubmed: 32492305
Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13:241–57. https://doi.org/10.1038/nrneph.2017.2 .
doi: 10.1038/nrneph.2017.2
pubmed: 28239173
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371:58–66. https://doi.org/10.1056/NEJMra1214243 .
doi: 10.1056/NEJMra1214243
pubmed: 24988558
pmcid: 9720902
Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43:816–28. https://doi.org/10.1007/s00134-017-4755-7 .
doi: 10.1007/s00134-017-4755-7
pubmed: 28364303
Zarbock A, Nadim MK, Pickkers P, et al. Sepsis-associated acute kidney injury: consensus report of the 28th acute disease quality initiative workgroup. Nat Rev Nephrol. 2023. https://doi.org/10.1038/s41581-023-00683-3 .
doi: 10.1038/s41581-023-00683-3
pubmed: 37653237
Zarbock A, Forni LG, Ostermann M, et al. Designing acute kidney injury clinical trials. Nat Rev Nephrol. 2024;20:137–46. https://doi.org/10.1038/s41581-023-00758-1 .
doi: 10.1038/s41581-023-00758-1
pubmed: 37653237
Doi K, Leelahavanichkul A, Yuen PST, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest. 2009;119:2868–78. https://doi.org/10.1172/JCI39421 .
doi: 10.1172/JCI39421
pubmed: 19805915
pmcid: 2752080
Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019;96:1083–99. https://doi.org/10.1016/j.kint.2019.05.026 .
doi: 10.1016/j.kint.2019.05.026
pubmed: 31443997
pmcid: 6920048
Bhavani SV, Semler M, Qian ET, et al. Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med. 2022;48:1582–92. https://doi.org/10.1007/s00134-022-06890-z .
doi: 10.1007/s00134-022-06890-z
pubmed: 36152041
pmcid: 9510534
Ozrazgat-Baslanti T, Loftus TJ, Ren Y, et al. Association of persistent acute kidney injury and renal recovery with mortality in hospitalised patients. BMJ Health Care Inform. 2021;28:e100458. https://doi.org/10.1136/bmjhci-2021-100458 .
doi: 10.1136/bmjhci-2021-100458
pubmed: 34876451
pmcid: 8655552
Ozrazgat-Baslanti T, Loftus TJ, Mohandas R, et al. Clinical trajectories of acute kidney injury in surgical sepsis: a prospective observational study. Ann Surg. 2022;275:1184–93. https://doi.org/10.1097/SLA.0000000000004360 .
doi: 10.1097/SLA.0000000000004360
pubmed: 33196489
Dépret F, Hollinger A, Cariou A, et al. Incidence and outcome of subclinical acute kidney injury using penkid in critically Ill patients. Am J Respir Crit Care Med. 2020;202:822–9. https://doi.org/10.1164/rccm.201910-1950OC .
doi: 10.1164/rccm.201910-1950OC
pubmed: 32516543
Hollinger A, Wittebole X, François B, et al. Proenkephalin A 119–159 (Penkid) is an early biomarker of septic acute kidney injury: the kidney in sepsis and septic shock (Kid-SSS) study. Kidney Int Rep. 2018;3:1424–33. https://doi.org/10.1016/j.ekir.2018.08.006 .
doi: 10.1016/j.ekir.2018.08.006
pubmed: 30450469
pmcid: 6224621
Molinari L, Del Rio-Pertuz G, Smith A, et al. Utility of biomarkers for sepsis-associated acute kidney injury staging. JAMA Netw Open. 2022;5:e2212709. https://doi.org/10.1001/jamanetworkopen.2022.12709 .
doi: 10.1001/jamanetworkopen.2022.12709
pubmed: 35583867
pmcid: 9118077
Fiorentino M, Xu Z, Smith A, et al. Serial measurement of cell-cycle arrest biomarkers [TIMP-2] · [IGFBP7] and risk for progression to death, dialysis, or severe acute kidney injury in patients with septic shock. Am J Respir Crit Care Med. 2020;202:1262–70. https://doi.org/10.1164/rccm.201906-1197OC .
doi: 10.1164/rccm.201906-1197OC
pubmed: 32584598
pmcid: 7605192
DeMerle KM, Angus DC, Baillie JK, et al. Sepsis subclasses: a framework for development and interpretation. Crit Care Med. 2021;49:748–59. https://doi.org/10.1097/CCM.0000000000004842 .
doi: 10.1097/CCM.0000000000004842
pubmed: 33591001
pmcid: 8627188
Bhatraju PK, Zelnick LR, Katz R, et al. A prediction model for severe AKI in critically Ill adults that incorporates clinical and biomarker data. Clin J Am Soc Nephrol. 2019;14:506–14. https://doi.org/10.2215/CJN.04100318 .
doi: 10.2215/CJN.04100318
pubmed: 30917991
pmcid: 6450340
Wiersema R, Jukarainen S, Vaara ST, et al. Two subphenotypes of septic acute kidney injury are associated with different 90-day mortality and renal recovery. Crit Care. 2020;24:150. https://doi.org/10.1186/s13054-020-02866-x .
doi: 10.1186/s13054-020-02866-x
pubmed: 32295614
pmcid: 7161019
Chaudhary K, Vaid A, Duffy Á, et al. Utilization of deep learning for subphenotype identification in sepsis-associated acute kidney injury. Clin J Am Soc Nephrol. 2020;15:1557–65. https://doi.org/10.2215/CJN.09330819 .
doi: 10.2215/CJN.09330819
pubmed: 33033164
pmcid: 7646246
Madushani RWMA, Patel V, Loftus T, et al. Early biomarker signatures in surgical sepsis. J Surg Res. 2022;277:372–83. https://doi.org/10.1016/j.jss.2022.04.052 .
doi: 10.1016/j.jss.2022.04.052
pubmed: 35569215
pmcid: 9827429
Reddy K, Sinha P, O’Kane CM, et al. Subphenotypes in critical care: translation into clinical practice. Lancet Respir Med. 2020;8:631–43. https://doi.org/10.1016/S2213-2600(20)30124-7 .
doi: 10.1016/S2213-2600(20)30124-7
pubmed: 32526190
Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2020;16:20–31. https://doi.org/10.1038/s41581-019-0199-3 .
doi: 10.1038/s41581-019-0199-3
pubmed: 31511662
Bhatraju PK, Zelnick LR, Herting J, et al. Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy. Am J Respir Crit Care Med. 2019;199:863–72. https://doi.org/10.1164/rccm.201807-1346OC .
doi: 10.1164/rccm.201807-1346OC
pubmed: 30334632
pmcid: 6444649
Wick KD, McAuley DF, Levitt JE, et al. Promises and challenges of personalized medicine to guide ARDS therapy. Crit Care. 2021;25:404. https://doi.org/10.1186/s13054-021-03822-z .
doi: 10.1186/s13054-021-03822-z
pubmed: 34814925
pmcid: 8609268
Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023;11:965–74. https://doi.org/10.1016/S2213-2600(23)00237-0 .
doi: 10.1016/S2213-2600(23)00237-0
pubmed: 37633303
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321:2003–17. https://doi.org/10.1001/jama.2019.5791 .
doi: 10.1001/jama.2019.5791
pubmed: 31104070
pmcid: 6537818
Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin b hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320:1455–63. https://doi.org/10.1001/jama.2018.14618 .
doi: 10.1001/jama.2018.14618
pubmed: 30304428
pmcid: 6233793
Klein DJ, Foster D, Walker PM, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44:2205–12. https://doi.org/10.1007/s00134-018-5463-7 .
doi: 10.1007/s00134-018-5463-7
pubmed: 30470853
pmcid: 6280819
Tomlinson G, Al-Khafaji A, Conrad SA, et al. Bayesian methods: a potential path forward for sepsis trials. Crit Care. 2023;27:432. https://doi.org/10.1186/s13054-023-04717-x .
doi: 10.1186/s13054-023-04717-x
pubmed: 37940985
pmcid: 10634134
Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419–30. https://doi.org/10.1056/NEJMoa1704154 .
doi: 10.1056/NEJMoa1704154
pubmed: 28528561
Wieruszewski PM, Bellomo R, Busse LW, et al. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023;27:175. https://doi.org/10.1186/s13054-023-04446-1 .
doi: 10.1186/s13054-023-04446-1
pubmed: 37147690
pmcid: 10163684
Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46:949–57. https://doi.org/10.1097/CCM.0000000000003092 .
doi: 10.1097/CCM.0000000000003092
pubmed: 29509568
pmcid: 5959265
Bellomo R, Wunderink RG, Szerlip H, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020;24:43. https://doi.org/10.1186/s13054-020-2733-x .
doi: 10.1186/s13054-020-2733-x
pubmed: 32028998
pmcid: 7006163
Bellomo R, Forni LG, Busse LW, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock: a clinical trial. Am J Respir Crit Care Med. 2020;202:1253–61. https://doi.org/10.1164/rccm.201911-2172OC .
doi: 10.1164/rccm.201911-2172OC
pubmed: 32609011
pmcid: 7605187
Legrand M, Bokoch MP. The Yin and Yang of the renin-angiotensin-aldosterone system in AKI. Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202012-4419ED .
doi: 10.1164/rccm.202012-4419ED
pubmed: 32516543
Ostermann M, Boldt DW, Harper MD, et al. Angiotensin in ECMO patients with refractory shock. Crit Care. 2018;22:288. https://doi.org/10.1186/s13054-018-2225-4 .
doi: 10.1186/s13054-018-2225-4
pubmed: 30382926
pmcid: 6211436
Gleeson PJ, Crippa IA, Mongkolpun W, et al. Renin as a marker of tissue-perfusion and prognosis in critically Ill patients. Crit Care Med. 2019;47:152–8. https://doi.org/10.1097/CCM.0000000000003544 .
doi: 10.1097/CCM.0000000000003544
pubmed: 30653055
Jeyaraju M, McCurdy MT, Levine AR, et al. Renin kinetics are superior to lactate kinetics for predicting in-hospital mortality in hypotensive critically Ill patients. Crit Care Med. 2022;50:50–60. https://doi.org/10.1097/CCM.0000000000005143 .
doi: 10.1097/CCM.0000000000005143
pubmed: 34166293
RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:1627–38. https://doi.org/10.1056/NEJMoa0902413 .
doi: 10.1056/NEJMoa0902413
Legrand M, Bagshaw SM, Koyner JL, et al. Optimizing the design and analysis of future AKI trials. J Am Soc Nephrol. 2022;33:1459–70. https://doi.org/10.1681/ASN.2021121605 .
doi: 10.1681/ASN.2021121605
pubmed: 35831022
pmcid: 9342638
Pickkers P, Mehta RL, Murray PT, et al. Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. JAMA. 2018;320:1998–2009. https://doi.org/10.1001/jama.2018.14283 .
doi: 10.1001/jama.2018.14283
pubmed: 30357272
pmcid: 6248164
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated…|BMJ Open. https://bmjopen.bmj.com/content/13/4/e065613 . Accessed 9 May 2023
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)|Intensive Care Medicine. https://doi.org/10.1007/s00134-023-07271-w . Accessed 3 Mar 2024
Rubin EB, Buehler AE, Halpern SD. States worse than death among hospitalized patients with serious illnesses. JAMA Intern Med. 2016;176:1557–9. https://doi.org/10.1001/jamainternmed.2016.4362 .
doi: 10.1001/jamainternmed.2016.4362
pubmed: 27479808
pmcid: 6848972
Atramont A, Lindecker-Cournil V, Rudant J, et al. Association of age with short-term and long-term mortality among patients discharged from intensive care units in France. JAMA Netw Open. 2019;2:e193215. https://doi.org/10.1001/jamanetworkopen.2019.3215 .
doi: 10.1001/jamanetworkopen.2019.3215
pubmed: 31074809
pmcid: 6512465
Martin GL, Atramont A, Mazars M, et al. Days spent at home and mortality after critical illness: a cluster analysis using nationwide data. Chest. 2023;163:826–42. https://doi.org/10.1016/j.chest.2022.10.008 .
doi: 10.1016/j.chest.2022.10.008
pubmed: 36257472
Villeneuve P-M, Clark EG, Sikora L, et al. Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit: a systematic review. Intensive Care Med. 2016;42:137–46. https://doi.org/10.1007/s00134-015-4151-0 .
doi: 10.1007/s00134-015-4151-0
pubmed: 26626062
Auriemma CL, O’Donnell H, Jones J, et al. Patient perspectives on states worse than death: a qualitative study with implications for patient-centered outcomes and values elicitation. Palliat Med. 2022;36:348–57. https://doi.org/10.1177/02692163211058596 .
doi: 10.1177/02692163211058596
pubmed: 34965775
Dinglas VD, Cherukuri SPS, Needham DM. Core outcomes sets for studies evaluating critical illness and patient recovery. Curr Opin Crit Care. 2020;26:489–99. https://doi.org/10.1097/MCC.0000000000000750 .
doi: 10.1097/MCC.0000000000000750
pubmed: 32773613
pmcid: 8314715
Andersen SK, Butler RA, Chang C-CH, et al. Prevalence of long-term decision regret and associated risk factors in a large cohort of ICU surrogate decision makers. Crit Care. 2023;27:61. https://doi.org/10.1186/s13054-023-04332-w .
doi: 10.1186/s13054-023-04332-w
pubmed: 36797793
pmcid: 9933411
Auriemma CL, Harhay MO, Haines KJ, et al. What matters to patients and their families during and after critical illness: a qualitative study. Am J Crit Care. 2021;30:11–20. https://doi.org/10.4037/ajcc2021398 .
doi: 10.4037/ajcc2021398
pubmed: 33385204
pmcid: 8101225
Hauschildt KE, Seigworth C, Kamphuis LA, et al. Financial toxicity after acute respiratory distress syndrome: a national qualitative cohort study. Crit Care Med. 2020;48:1103–10. https://doi.org/10.1097/CCM.0000000000004378 .
doi: 10.1097/CCM.0000000000004378
pubmed: 32697479
pmcid: 7387748
Arnup SJ, McKenzie JE, Hemming K, et al. Understanding the cluster randomised crossover design: a graphical illustraton of the components of variation and a sample size tutorial. Trials. 2017;18:381. https://doi.org/10.1186/s13063-017-2113-2 .
doi: 10.1186/s13063-017-2113-2
pubmed: 28810895
pmcid: 5557529
Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically Ill adults. N Engl J Med. 2018;378:829–39. https://doi.org/10.1056/NEJMoa1711584 .
doi: 10.1056/NEJMoa1711584
pubmed: 29485925
pmcid: 5846085
Toporek AH, Semler MW, Self WH, et al. Balanced crystalloids versus saline in critically Ill adults with hyperkalemia or acute kidney injury: secondary analysis of a clinical trial. Am J Respir Crit Care Med. 2021;203:1322–5. https://doi.org/10.1164/rccm.202011-4122LE .
doi: 10.1164/rccm.202011-4122LE
pubmed: 33503391
pmcid: 8456473
I-SPY COVID Consortium. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. EClinicalMedicine. 2023;58:101889. https://doi.org/10.1016/j.eclinm.2023.101889 .
doi: 10.1016/j.eclinm.2023.101889
Kent DM, Paulus JK, van Klaveren D, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med. 2020;172:35–45. https://doi.org/10.7326/M18-3667 .
doi: 10.7326/M18-3667
pubmed: 31711134
Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19: a randomized clinical trial. JAMA. 2023;329:1183–96. https://doi.org/10.1001/jama.2023.4480 .
doi: 10.1001/jama.2023.4480
pmcid: 10326520
Zampieri FG, Damiani LP, Bagshaw SM, et al. Conditional treatment effect analysis of two infusion rates for fluid challenges in critically Ill patients: a secondary analysis of balanced solution versus saline in intensive care study (BaSICS) trial. Ann Am Thorac Soc. 2023. https://doi.org/10.1513/AnnalsATS.202211-946OC .
doi: 10.1513/AnnalsATS.202211-946OC
pubmed: 37909798
pmcid: 10632926
Seitz KP, Spicer AB, Casey JD, et al. Individualized treatment effects of bougie vs stylet for tracheal intubation in critical illness. Am J Respir Crit Care Med. 2023. https://doi.org/10.1164/rccm.202209-1799OC .
doi: 10.1164/rccm.202209-1799OC
pubmed: 36877594
Seymour CW, Gomez H, Chang C-CH, et al. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017;21:257. https://doi.org/10.1186/s13054-017-1836-5 .
doi: 10.1186/s13054-017-1836-5
pubmed: 29047353
pmcid: 5648512
Stanski NL, Rodrigues CE, Strader M, et al. Precision management of acute kidney injury in the intensive care unit: current state of the art. Intensive Care Med. 2023;49:1049–61. https://doi.org/10.1007/s00134-023-07171-z .
doi: 10.1007/s00134-023-07171-z
pubmed: 37552332
Ham KR, Boldt DW, McCurdy MT, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Ann Intensive Care. 2019;9:63. https://doi.org/10.1186/s13613-019-0536-5 .
doi: 10.1186/s13613-019-0536-5
pubmed: 31161442
pmcid: 6546778